Journal: Frontiers in Immunology
Article Title: Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1
doi: 10.3389/fimmu.2023.1204834
Figure Lengend Snippet: SARS-CoV-2 RBD-nano vaccine induces high neutralizing antibodies titers. Antibodies induced by the different vaccine formulations and neutralizing antibodies titers were quantified at (A, B) 28 days, (C, D) 42 days after receiving the first immunization dose, and (E, F) at the day of necropsy 46 days after immunization. IgG antibodies (A, C, E) were detected by RBD-ELISA, and dotted lines indicate the assay cutoff value ( x ¯ + 2 S D ) based on the control group. Neutralizing antibodies titers (B, D, F) are expressed as the reciprocal of the dilution that gave a 50% reduction of stained cells. P-values were calculated by a two-way ANOVA test; mean ± SD are presented. ****p< 0.0001; ***p< 0.001; **p< 0.01; *p< 0.05.
Article Snippet: After 1 h of incubation at 37°C, a 1:50 dilution of the serum samples was added, and plates were incubated, washed, and incubated with a 1:4,000 dilution of goat anti-Syrian hamster Immunoglobulin G (IgG) H&L conjugated to horse radish peroxidase (Abcam).
Techniques: Enzyme-linked Immunosorbent Assay, Staining